Abortion Stigma as a Barrier to Mifepristone Use among Obstetrician-Gynecologists in Alabama for Early Pregnancy Loss

被引:0
|
作者
Mokashi, Mugdha [1 ]
Boulineaux, Christina [2 ]
Janiak, Elizabeth [3 ]
Boozer, Margaret [4 ]
Neill, Sara [5 ]
机构
[1] Northwestern Univ, Feinberg Sch Med, Dept Obstet & Gynecol, 250 E Super St,Suite 03-2303, Chicago, IL 60611 USA
[2] Harvard Med Sch, Boston, MA USA
[3] Brigham & Womens Hosp, Dept Obstet Gynecol & Reprod Biol, Boston, MA USA
[4] Univ Alabama Birmingham, Dept Obstet & Gynecol, Birmingham, AL USA
[5] Harvard Med Sch, Dept Obstet Gynecol & Reprod Biol, Beth Israel Deaconess Med Ctr, Boston, MA USA
关键词
abortion stigma; Alabama; early pregnancy loss; mifepristone; obstetrician-gynecologist; MEDICAL-MANAGEMENT; MISSED MISCARRIAGE; DOUBLE-BLIND; MISOPROSTOL; PRETREATMENT; EFFICACY; CARE;
D O I
10.14423/SMJ.0000000000001717
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: The objective of our study was to identify and characterize barriers to mifepristone use among obstetrician-gynecologists (OB-GYNs) for early pregnancy loss in a southern US state. Methods: In this qualitative study, we conducted semistructured interviews with 19 OB-GYNs in Alabama who manage early pregnancy loss. The interviews explored participants' knowledge of and experience with mifepristone use for miscarriage management and abortion, along with barriers to and facilitators of clinical mifepristone use. The interviews were coded by multiple study staff using inductive and deductive thematic coding. Results: Nearly all of the interviewees identified abortion-related stigma as a barrier to mifepristone use. Interviewees often attributed stigma to a lack of knowledge about the clinical use of mifepristone for early pregnancy loss. The stigmatization of mifepristone due to its association with abortion was related to religious and political objections. Many interviewees also described stigma associated with misoprostol use. Although providers believed that mifepristone use for abortion would not be accepted in their practice, most believed that mifepristone could be used successfully for miscarriage management after practice-wide education on its use. Conclusions: Mifepristone is strongly associated with abortion stigma among OB-GYNs in Alabama, which is a barrier to its use for miscarriage management. Interventions to decrease abortion stigma and associated stigma surrounding mifepristone are needed to optimize early pregnancy loss care.
引用
收藏
页码:504 / 509
页数:6
相关论文
共 10 条
  • [1] Management of early pregnancy loss among obstetrician-gynecologists in Massachusetts and barriers to mifepristone use
    Neill, Sara
    Hoe, Emily
    Fortin, Jennifer
    Goldberg, Alisa B.
    Janiak, Elizabeth
    CONTRACEPTION, 2023, 126
  • [2] Spatial Disparities in Mifepristone Use for Early Miscarriage and Induced Abortion Among Obstetrician-Gynecologists Practicing in Massachusetts
    Newton-Hoe, Emily
    Goldberg, Alisa B.
    Fortin, Jennifer
    Janiak, Elizabeth
    Neill, Sara
    WOMENS HEALTH REPORTS, 2024, 5 (01): : 765 - 774
  • [3] Mifepristone Use Among Obstetrician-Gynecologists in Massachusetts: Prevalence and Predictors of Use
    Newton-Hoe, Emily
    Lee, Alice
    Fortin, Jennifer
    Goldberg, Alisa B.
    Janiak, Elizabeth
    Neill, Sara
    WOMENS HEALTH ISSUES, 2024, 34 (02) : 135 - 141
  • [4] Abortion Referral Practices among a National Sample of Obstetrician-Gynecologists
    Daniel, Sara
    Schulkin, Jay
    Grossman, Daniel
    WOMENS HEALTH ISSUES, 2020, 30 (06) : 446 - 452
  • [5] Mifepristone and Misoprostol for Early Pregnancy Loss and Medication Abortion
    Macnaughton, Honor
    Nothnagle, Melissa
    Early, Jessica
    AMERICAN FAMILY PHYSICIAN, 2021, 103 (08) : 473 - 480
  • [6] Mifepristone use for early pregnancy loss: A qualitative study of barriers and facilitators among OB/GYNS in Massachusetts, USA
    Neill, Sara
    Mokashi, Mugdha
    Goldberg, Alisa
    Fortin, Jennifer
    Janiak, Elizabeth
    PERSPECTIVES ON SEXUAL AND REPRODUCTIVE HEALTH, 2023, 55 (03) : 210 - 217
  • [7] Obstetrician-gynecologists' practice patterns related to opioid use during pregnancy and postpartum-United States, 2017
    Ko, Jean Y.
    Tong, Van T.
    Haight, Sarah C.
    Terplan, Mishka
    Snead, Carrie
    Schulkin, Jay
    JOURNAL OF PERINATOLOGY, 2020, 40 (03) : 412 - 421
  • [8] US clinicians' perspectives on how mifepristone regulations affect access to medication abortion and early pregnancy loss care in primary care
    Srinivasulu, Silpa
    Yavari, Roya
    Brubaker, Libby
    Riker, Laura
    Prine, Linda
    Rubin, Susan E.
    CONTRACEPTION, 2021, 104 (01) : 92 - 97
  • [9] Streamlining the Use of Mifepristone for Early Pregnancy Loss Across a Large Health Care System Sets the Stage for Rapid Expansion of Medication Abortion Access in a Post-Roe Environment
    Chaisson, Nicole
    Schafer, Katherine Montag
    ANNALS OF FAMILY MEDICINE, 2023, 21 (05) : 469 - 469
  • [10] Randomized trial assessing home use of two pregnancy tests for determining early medical abortion outcomes at 3, 7 and 14 days after mifepristone
    Blum, Jennifer
    Sheldon, Wendy R.
    Nguyen Thi Nhu Ngoc
    Winikoff, Beverly
    Nguyen Thi Bach Nga
    Martin, Roxanne
    Le Van Thanh
    Blumenthal, Paul D.
    CONTRACEPTION, 2016, 94 (02) : 115 - 121